Fig. 1: Trial profile. | Eye

Fig. 1: Trial profile.

From: Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients

Fig. 1: Trial profile.

A total of 132 patients were screened and, after 38 withdrawals, a total of 94 patients were randomized to each of the treatment groups, Arm 1 (umedaptanib pegol monotherapy), Arm 2 (umedaptanib pegol + aflibercept combination therapy), and Arm 3 (aflibercept monotherapy), and subjected to clinical trials.

Back to article page